Sort
15,273 grants matching “antimicrobial resistance”
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)
$3,193,195Karen Marie Dobos · Colorado State University · G20 · FY2022 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities
$3,190,133David R Andes · University Of Wisconsin-Madison · U19 · FY2017 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities
$3,190,133David R Andes · University Of Wisconsin-Madison · U19 · FY2016 · AI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$3,184,516Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2016 · AI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$3,184,516Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2016 · AI
Vaccine and Treatment Evaluation Units
$3,175,510Nadine Georges Rouphael · Emory University · UM1 · FY2022 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,143,754Jerrold J. Ellner · Boston Medical Center · U19 · FY2014 · AI
Treatment of Infections in Immunocompromised Children with Cancer, Hematopoietic
$3,141,379Thomas J Walsh · Clinical Sciences · Z01 · FY2007 · CA
Optimizing anti-microbial immunity by targeting Sts-1
$3,125,627Nicholas A Carpino · State University New York Stony Brook · R01 · FY2025 · AI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
$3,109,945Carole D Mitnick · Harvard Medical School · U01 · FY2011 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities
$3,097,773David R Andes · University Of Wisconsin-Madison · U19 · FY2018 · AI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
$3,094,141Carole D Mitnick · Harvard Medical School · U01 · FY2012 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,078,872Jerrold J. Ellner · Boston Medical Center · U19 · FY2016 · AI
MIDAS Center for Communicable Disease Dynamics
$3,078,763Marc Lipsitch · Harvard School Of Public Health · U54 · FY2010 · GM
Bronchiectasis and chronic airway infection
$3,066,862Kenneth Olivier · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,064,926Jerrold J. Ellner · Boston Medical Center · U19 · FY2017 · AI
PRECLINICAL DEVELOPMENT OF AN ANTIMICROBIAL NANOEMULSION TO IND FOR MULTIDRUG-RESISTANT WOUND INFECTIONS
$3,058,913Regents Of The University Of Michigan · · FY2015 · Department of the Army
Innovative technologies to transform antibiotic discovery. Administrative Core
$3,052,404Deborah T Hung · Broad Institute, Inc. · U19 · FY2020 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,050,511Jerrold J. Ellner · Boston Medical Center · U19 · FY2015 · AI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$3,023,963Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2014 · AI
Task 11: Interventional Agent Development Services Program
$3,017,090Jon Mirsalis · Sri International · N01 · FY2017 · AI
Dietary Fiber-Microbiome Interactions: Elucidating Mechanisms to Suppress Multi-Drug Resistant Organisms in the Human Gut
$3,012,181Ophelia Venturelli · Duke University · R01 · FY2025 · AI
Targeted Clinical Trial to Reduce the Risk of Antimicrobial Resistance
$3,009,340Victor Yu · University Of Pittsburgh At Pittsburgh · N01 · FY2010 · AI
Novel antibacterial agents for treatment of Tularemia
$2,995,855Affinium Pharmaceuticals, Inc. · U01 · FY2004 · AI
GH19-005, Advancing Public Health Research in Bangladesh
$2,987,356Sayera Banu · International Ctr/Diarrhoeal Dis Res · U01 · FY2020 · GH